Among them, HLA class I antigens, the co-stimulatory molecule ICAM-1, and tumor-associated antigens (TAA), such as the cancer testis antigens (CTAs) NY-ESO-1 and MAGE-A3 that are considered suitable therapeutic targets due to their high immunogenic potential (Coral et al., 1999, 2013). This evidence concerns the gene ICAM1 and cancer.